CCR4 and allergic respiratory disease: A number of small-molecule CCR4 antagonists have shown promising results in various animal models of inflammation, such as reduction in ovalbumin-induced ear swelling in mice[34], inhibition of ovalbumin-induced airway inflammation in guinea pigs[35] and a reduction in the recruitment of Th2 cells to the lungs in a mouse model of ovalbumin-induced airway allergy[36].